Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Human Papillomavirus Infection

Human Papillomavirus Infection

Part of HPV infection

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Human Papillomavirus Infection

30 trials tracked for Human Papillomavirus Infection: 11 in phase 3 or 4 and 5 with published results. The most-cited published study has 210 citations.

30Trials tracked
11Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 3 Phase 3 8 Phase 2 3 Other / NA 16
  1. Phase 3 A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) Completed · 210 cited
  2. Phase 3 Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009) Completed · 120 cited
  3. Phase 3 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed · 40 cited
  4. Phase 4 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Completed · 14 cited
  5. Phase 4 Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine Completed · 8 cited
  6. Phase 4 Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers Completed
Show 24 more trials
  1. Phase 3 Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System Completed
  2. Phase 3 A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) Completed
  3. Phase 3 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed
  4. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Completed
  5. Phase 3 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. Completed
  6. Phase 2 Study of Gardasil in Mid-Adult Males (MAM) Completed
  7. Phase 2 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Completed
  8. Phase 2 Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Completed
  9. N/A HPV Typing Between Self- and Physician-sampled Completed
  10. N/A Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting Completed
  11. N/A The Human Papilloma Virus Effect on Sexual Life Completed
  12. N/A txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men Completed
  13. N/A Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination Completed
  14. N/A Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV Completed
  15. N/A Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV Completed
  16. N/A GARDASIL Reexamination Study (V501-059) Completed
  17. N/A Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study Completed
  18. N/A Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia Completed
  19. N/A Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031) Completed
  20. N/A Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents Completed
  21. N/A Prospective Evaluation of Self-Testing to Increase Screening Completed
  22. N/A A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates Completed
  23. N/A Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention Completed
  24. N/A Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Human Papillomavirus Infection: what the trials found

Multiple trials evaluated the efficacy and immunogenicity of various HPV vaccines, including Gardasil, Cervarix, and V503 (9-valent human papillomavirus L1 virus-like particle vaccine). Clinical data demonstrate high seropositivity rates for these vaccines; specifically, 100% of participants were seropositive for HPV types 6/11/16/18 in several studies [4, 5, 14]. V503 demonstrated significant geometric mean titers (GMTs) against various HPV types including 6, 11, 16, and 18 across multiple trials [4, 6, 8], with some results showing high statistical significance (p < 0.001).

Comparative studies for Gardasil showed a significantly lower incidence of disease related to HPV types 31/33/45/52/58 compared to the control group 9. Additionally, trials evaluating Cervarix and other vaccine formulations reported high rates of successful seroconversion and meeting acceptable antibody titers for associated conditions like diphtheria and tetanus [10, 11].

One study specifically assessed the impact of modified vaccination schedules on completion rates among female sex workers; no significant difference was found in completion rates between a 3-month and 6-month schedule (p=0.60), nor were there significant differences in the prevalence of HPV infection between groups 3.

Recent results — preliminary, needs further review

  • Telephone recall systems were evaluated as an intervention 15.
  • Conventional text message reminders were utilized as a reminder method 16.

For the clinician treating this condition

  • HPV vaccines (Gardasil, Cervarix, and V503) consistently demonstrate high seropositivity and robust antibody responses against major HPV types.
  • V503 shows statistically significant geometric mean titers across multiple study cohorts for protection against various HPV strains.
  • Modified vaccination schedules did not significantly impact the completion rates of the vaccine series in specific populations.

AI synthesis of 4 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oral HPV detected in 27.9% of men living with HIV across Brazil, Mexico, and Puerto Rico
Infectious Disease RCT
Oral HPV detected in 27.9% of men living with HIV across Brazil, Mexico, and Puerto Rico Oral HPV found in 28 percent of HIV-positive men in Brazil, Mexico, and Puerto Rico
This cross-sectional study examined 700 men living with HIV in Brazil, Mexico, and Puerto Rico. Oral HPV was detected in 27.9% of participan…
A cross-sectional study found oral HPV in 28 percent of men living with HIV across three countries, with higher rates linked to lower CD4 co…
Jun 1, 2026
Systematic review and meta-analysis of HPV vaccine awareness and uptake in Cameroon
Infectious Disease Meta-analysis
Systematic review and meta-analysis of HPV vaccine awareness and uptake in Cameroon Only 22.9 percent of Cameroon participants received the HPV vaccine despite high awareness among doctors
This systematic review and meta-analysis synthesizes data from 33 studies involving 8,175 participants in Cameroon regarding HPV vaccine awa…
In Cameroon, only 22.9 percent of people got the HPV vaccine. While doctors recommend it, knowledge gaps and changing attitudes are blocking…
medRxiv Apr 30, 2026
Systematic review and meta-analysis of HPV knowledge prevalence and associated factors in Cameroon
Infectious Disease
Systematic review and meta-analysis of HPV knowledge prevalence and associated factors in Cameroon Low HPV Knowledge Leaves Many Women at Risk in Cameroon
This systematic review and meta-analysis pooled data from 32 studies involving 13,457 participants in Cameroon to assess HPV-related knowled…
Most women in Cameroon lack very basic knowledge about HPV and cervical cancer risks and how it spreads.
medRxiv Apr 29, 2026
Narrative review on ICIs in patients with viral infections and solid tumors
Allergy & Immunology Sys. Review
Narrative review on ICIs in patients with viral infections and solid tumors Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Frontiers Apr 27, 2026
Systematic review examines innate immune recognition and PRR activation in HPV infection and cervical cancer progression
Infectious Disease Sys. Review
Systematic review examines innate immune recognition and PRR activation in HPV infection and cervical cancer progression How HPV Outsmarts Your Body's First Line of Defense
This mini-review synthesizes evidence regarding innate immune recognition, pattern recognition receptor activation, and HPV evasion strategi…
HPV evades the immune system by silencing its alarms, fueling cervical cancer and pointing to new ways to prevent it.
Frontiers Apr 15, 2026
Focused ultrasound shows HPV clearance, LSIL resolution in meta-analysis of observational studies
Oncology Meta-analysis
Focused ultrasound shows HPV clearance, LSIL resolution in meta-analysis of observational studies Focused ultrasound shows promise for treating cervical cell changes and HPV
A meta-analysis of observational studies in women with cervical LSIL and concurrent hrHPV infection found focused ultrasound treatment was a…
Focused ultrasound cleared HPV in 74% of women and returned cervical cell changes to normal in 94%, outperforming observation and interferon…
Apr 4, 2026
CDC updates human papillomavirus vaccination recommendations for U.S. adults
Allergy & Immunology
CDC updates human papillomavirus vaccination recommendations for U.S. adults CDC Updates HPV Vaccine Recommendations for Adults in the United States
The CDC has issued updated recommendations for human papillomavirus vaccination in U.S.
CDC updated HPV vaccine recommendations for U.S. adults after reviewing new evidence on safety and effectiveness.
CDC Apr 4, 2026
HPV vaccination coverage trends observed among adolescent girls in U.S.-affiliated Pacific Islands
Pediatrics
HPV vaccination coverage trends observed among adolescent girls in U.S.-affiliated Pacific Islands Study examines HPV vaccination trends for teens in U.S.-affiliated Pacific Islands
An observational report described HPV vaccination coverage trends among adolescent girls aged 13-17 years in U.S.-affiliated Pacific Islands…
A new report tracks HPV vaccination trends for teen girls living in U.S.-affiliated Pacific Islands to understand how coverage has changed o…
CDC Apr 4, 2026
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Oncology RCT
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…
Mar 30, 2026

Research across HPV infection

Related studies from across the HPV infection family.

Survey finds physicians show stronger intergroup bias than public on vaccines
Infectious Disease
Survey finds physicians show stronger intergroup bias than public on vaccines Doctors Show Strong Bias Against Vaccine-Hesitant Patients
This review of an online survey in Japan involving 492 physicians and 5,252 members of the general public found that physicians exhibited hi…
Doctors often see themselves as targets of vaccine anger, but new data shows they also hold strong bias against patients who question vaccin…
medRxiv Apr 26, 2026
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens
Infectious Disease Sys. Review
Narrative review outlines VLP engineering strategies for broadly protective vaccines against multiple viral pathogens New Vaccine Map Helps Pick Best Tools
This narrative review examines virus-like particle (VLP) engineering strategies, including genetic fusion, modular conjugation, and nucleic …
Imagine trying to fix a leaky roof with every tool in the shed.
Frontiers Apr 23, 2026
Virome and mycobiome roles in female reproductive tract health are increasingly recognized as potential ecosystem modulators
Allergy & Immunology Sys. Review
Virome and mycobiome roles in female reproductive tract health are increasingly recognized as potential ecosystem modulators Viruses and Fungi Hold the Key to Vaginal Health
This systematic scoping review examined the impact of the virome and mycobiome on female reproductive tract health compared to a bacteriocen…
Doctors need to look at the whole microbial team, not just the bacteria, to fix vaginal infections.
Frontiers Apr 12, 2026